Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

3.7K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
3.7K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

146
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
146

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Antibodies raised against a structurally defined Aβ oligomer mimic protect human iPSC neurons from Aβ toxicity at sub-stoichiometric concentrations.

PloS one·2025
Same author

Mini-αA-crystallin protects a client lens protein from catastrophic aggregation due to heat stress.

Protein science : a publication of the Protein Society·2025
Same author

A β-hairpin peptide derived from Aβ forms different oligomers in the crystal state and in aqueous solution.

Organic & biomolecular chemistry·2025
Same author

Potent Analogues of Clovibactin from Commercially Available Amino Acid Building Blocks.

The Journal of organic chemistry·2025
Same author

α-Methylation Enables the X-ray Crystallographic Observation of Oligomeric Assemblies Formed by a β-Hairpin Peptide Derived from Aβ.

The Journal of organic chemistry·2024
Same author

Teixobactin "Swapmers" with l Tail Stereochemistry Retain Antibiotic Activity.

The Journal of organic chemistry·2024
Same journal

A Ni-Mediated Cross-Coupling Approach to Deuterated <sup>18</sup>F- Fluoromethylated (Hetero)arenes.

Journal of the American Chemical Society·2026
Same journal

Efficient Light-Driven CO<sub>2</sub> Capture and Reversible Release Enabled by Metastable Photoacid-Decorated Metal-Organic Frameworks.

Journal of the American Chemical Society·2026
Same journal

In Situ Raman Spectroscopy Reveals the Dynamic Evolution and Ethanol Dependence of SEI Structure in Li-Mediated N<sub>2</sub> Reduction Reaction.

Journal of the American Chemical Society·2026
Same journal

Solvent Esterification and Stoichiometric Control in Ambient-Grown FAPbI<sub>3</sub> Single-Crystal Solar Cells.

Journal of the American Chemical Society·2026
Same journal

Unlocking Azulene Functionalization via Strain-Induced Azulyne Intermediates.

Journal of the American Chemical Society·2026
Same journal

An Oxazine-Locked Covalent Organic Framework by a Tandem Pinner/Schiff Base Reaction for Hydrogen Peroxide Photosynthesis.

Journal of the American Chemical Society·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 30, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.3K

バンコミシン-テイクソバクチン結合体

Maria Sophia Teresa Lee Padilla1, James S Nowick1,2,3

  • 1Department of Chemistry, University of California, Irvine, Irvine, California 92697, United States.

Journal of the American Chemical Society
|February 14, 2025
PubMed
まとめ
この要約は機械生成です。

ヴァンコマイシンとテイクソバクチンの薬剤結合は,耐性菌に対する有効性を高めます. この新しいアプローチはMRSAやVREのような 挑戦的な病原体に対する活性を増強します

さらに関連する動画

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.0K

関連する実験動画

Last Updated: Apr 30, 2026

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
10:39

Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity

Published on: June 25, 2015

12.3K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.0K

科学分野:

  • 薬剤化学
  • 微生物学
  • 薬物の発見

背景:

  • バンコミシンは薬剤耐性感染症の 重要な最後の手段である.
  • ヴァンコミシン耐性腸球菌 (VRE) のようなヴァンコミシン耐性菌株の出現は,新しい治療戦略を必要とします.

研究 の 目的:

  • 結合によってバンコマイシンの抗生物質作用の強化を調査する.
  • 耐性グラム陽性病原体に対して有効な新しい結合剤を開発する.

主な方法:

  • ヴァンコミシンを改変したテイクソバクチン製薬剤に結合する (残留物1−6は芳香性アミドに置き換えられる).
  • メチシリン耐性ステーキ菌 (MRSA),メチシリン感受性ステーキ菌 (MSSA),およびVREに対する最小抑制濃度 (MIC) の評価

主要な成果:

  • 単独の成分と比較してMRSAとMSSAに対する活性が著しく強化された3つのバンコミシン- テイクソバクチン結合体を特定した.
  • 個々の成分が無効である場合でも,これらの結合体がVREに対する活性を維持することを実証した.
  • 最も強力なコンジュガットはMRSAに対するMICは0. 5μg/ mlであり,MSSAに対するMICは0. 063- 0. 125μg/ mlであった.

結論:

  • ヴァンコミシンを最小限のテイクソバクチン製薬剤と結合させることは,抗生物質耐性を克服するための有効な戦略です.
  • このアプローチは 難しいグラム陽性細菌感染症に対する 新しい治療法の開発に 有望な機会を提供します